Image

Studies of Disorders With Increased Susceptibility to Fungal Infections

Studies of Disorders With Increased Susceptibility to Fungal Infections

Recruiting
All
Phase N/A

Powered by AI

Overview

Background
  • Researchers are interested in studying disorders that make individuals more susceptible to fungal infections, specifically infections with the Candida yeast. These disorders are often related to problems with the immune system and may have genetic factors, which suggests that researchers should study not only the individual with the disorder, but also his or her first- and second-degree relatives (such as parents, siblings, children, and first cousins). To provide material for future research, individuals with immune disorders and their firstand second-degree relatives will be asked to provide blood and other samples for testing and comparison with samples taken from healthy volunteers with no history of immune disorders.
    Objectives
  • To collect blood and other biological samples to study immune disorders that make individuals more susceptible to fungal infections.
    Eligibility
  • Individuals of any age who have abnormal immune function characterized by recurrent or unusual fungal infections, recurrent or chronic inflammation, or other types of immune dysfunction.
  • First- or second-degree genetically related family members (limited to mother, father, siblings, grandparents, children, aunts, uncles, and first cousins).
  • Healthy volunteers at least 18 years of age (for comparison purposes).
    Design
  • Participants will provide blood samples and buccal (cells from the inside of the mouth near the cheek) samples.
  • Participants with immune disorders will also be asked to provide urine samples, saliva or mucosal samples, or skin tissue biopsies, and may also have imaging studies (such as x-rays) to collect information for research.
  • Samples may be collected at the National Institutes of Health or at other clinical locations for the samples to the sent to the National Institutes of Health.
  • No treatment will be provided as part of this protocol.

Description

This study is designed for the evaluation, diagnosis, and long-term follow up of selected patients with primary immune deficiencies and other conditions associated with fungal, and more specifically with Candida spp. infections. The primary immune deficiencies to be studied include, but are not limited to, autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED), chronic mucocutaneous candidiasis (CMC), myeloperoxidase deficiency (MPO), immune dysregulation polyendocrinopathy enteropathy X-linked (IPEX), Job s syndrome, chronic granulomatous disease (CGD), and biotinidase deficiency. Diabetic patients and infants also show increased susceptibility to such infections and might be studied. Patient participants (who we will refer to as patients in this study) will undergo evaluations that include history/physical, blood sampling, genetic testing, and possible tissue sampling. We may use some of the blood cells to investigate the utility of induced pluripotent stem cells (iPS) for immune cell derivation and targeted gene correction. First or second degree genetically related family members (limited to mother, father, siblings, grandparents, children, aunts, uncles, and first cousins of an affected patient and who we will refer to as relatives in this study) might also be screened for clinical, in vitro, and genetic correlates of immune abnormalities. Healthy volunteers will be enrolled as a source of control samples for research testing. Among the aims of this protocol are to better understand the genetic and pathophysiologic factors that lead to defects in host defense, and to use modern and evolving methods in molecular and cellular biology to elucidate the pathogenesis of this particular susceptibility. A better understanding of primary immunodeficiency could allow for the rational development of novel therapies for such diseases and to benefit future patients, but it might not benefit current patient participants directly. Routine follow-up may occur every 6 months -with evaluation and blood sampling. Under some circumstances, we may provide treatment that relates to the immune deficiency. These treatments will follow standard medical practice.

Eligibility

  • INCLUSION CRITERIA:

Patient Participants (or simply Patient):

        Patients with abnormalities of immune function as manifested by recurrent or unusual fungal
        infections, recurrent or chronic inflammation, or previous laboratory evidence of immune
        dysfunction are eligible for screening and assessment under this protocol. Of particular
        focus of this study are patients with:
          -  APECED (autoimmune polyendocrinopathy candidiasis ectodermal dystrophy)
          -  CMC (chronic mucocutaneous candidiasis)
          -  MPO (myeloperoxidase deficiency)
          -  IPEX (immune dysregulation polyendocrinopathy enteropathy X-linked)
          -  Hyper-immunoglobulin E syndrome (Job s syndrome)
          -  CGD (chronic granulomatous disease)
          -  Biotinidase deficiency
          -  Other conditions showing increased susceptibility to such infections as described in
             infants and type 1 diabetic patientts
        There will be no limit due to age, sex, race, or disability.
        All patients must have a primary physician outside of the NIH.
        Women of child-bearing potential, or who are pregnant or lactating, may be eligible.
        All patients will be required to have blood stored for future studies and/or other medical
        conditions.
        Relatives:
        Relatives may be mother, father, siblings, children, grandparents, aunts, uncles, and first
        cousins to a patient participant.
        There is no limit due to age, sex, race, or disability.
        Relatives will be required to have blood stored for future studies and/or other medical
        conditions.
        Healthy volunteers must:
        Be an adult of either sex and between age of 18 and 85 years old
        Have a hemoglobin concentration of greater than or equal to 11 g/dL
        Weigh greater than or equal to 110 pounds
        EXCLUSION CRITERIA:
        Patient:
        The presence of certain types of acquired abnormalities of immunity solely due to human
        immunodeficiency virus (HIV), chemotherapeutic agent(s), or an underlying malignancy could
        be grounds for possible exclusion for a subject.
        Relatives:
        The presence of certain types of acquired abnormalities of immunity solely due to HIV,
        chemotherapeutic agent(s), or an underlying malignancy could be grounds for possible
        exclusion for a relative.
        Healthy volunteers are not eligible if:
        Receiving chemotherapeutic agent(s), or have underlying malignancy
        Pregnant or lactating
        Have history of heart, lung, kidney disease, bleeding or immunologic disorders leading to
        significant incapacity
        Have a history of recurrent or severe infections
        Have a history of HIV seropositivity
        Have a history of viral hepatitis (B or C)

Study details
    Fungal Infections
    Primary Immune Deficiencies

NCT01222741

National Institute of Allergy and Infectious Diseases (NIAID)

17 June 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.